Inmune Bio, Inc. (INMB) Form 8-K — Oct 29, 2026
$INMBForm 8-KItems 1.01, 3.02, 7.01, 9.01Filed Oct 29, 2026, 7:40 AM ET0001213900-26-113535Original filing
INmune Bio entered a securities purchase agreement on October 27, 2026 with a single investor for a registered direct offering of 3,000,000 shares at $1.50 per share, with a concurrent private placement of warrants for 3,000,000 additional shares at a $1.65 exercise price. The company expects gross proceeds of $4.5 million before fees, with the offering closing on October 29, 2026. A.G.P./Alliance Global Partners acted as sole placement agent on a reasonable best efforts basis, earning a 7.0% cash fee plus up to $125,000 in expense reimbursements.
Key figures
- Debt Amount
- 0
- Gross Proceeds
- 4500000
- Offering Price
- 1.5
- Shares Offered
- 3000000
- Warrant shares
- 3000000
- Warrant expiration
- 2032-04-27
- Placement agent fee
- 7.0% of gross proceeds
- Warrant exercise price
- 1.65
- Warrant exercise start
- 2027-04-27
- Non accountable expenses
- 25000
- Beneficial ownership limit
- 9.99% (max 19.99%)
- Legal expense reimbursement
- 100000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.